. . "Potenciace hypoglykemick\u00E9ho \u00FA\u010Dinku a tedy v n\u011Bkter\u00FDch p\u0159\u00EDpadech v\u00FDskyt hypoglykemie se m\u016F\u017Ee objevit p\u0159i pod\u00E1v\u00E1n\u00ED n\u011Bkter\u00E9ho z n\u00E1sleduj\u00EDc\u00EDch p\u0159\u00EDpravk\u016F:\n- fenylbutazon, azapropazon a oxyfenylbutazon\n- inzul\u00EDn a peror\u00E1ln\u00ED antidiabetika, jako metformin\n- salicyl\u00E1ty a p-amino-salicylov\u00E1 kyselina\n- anabolick\u00E9 steroidy a mu\u017Esk\u00E9 pohlavn\u00ED hormony\n- chloramfenikol, n\u011Bkter\u00E9 dlouhodob\u011B p\u016Fsob\u00EDc\u00ED sulfonamidy, tetracykliny, chinolonov\u00E1 antibiotika a klarithromycin\n- kumarinov\u00E1 antikoagulancia\n- fenfluramin\n- disopyramid\n- fibr\u00E1ty\n- ACE inhibitory\n- fluoxetin, inhibitory MAO\n- alopurinol, probenecid, sulfinpyrazon\n- sympatolytika\n- cyklofosfamid, trofosfamid a ifosfamid\n- mikonazol, flukonazol\n- pentoxifylin (vysok\u00E9 parenter\u00E1ln\u00ED d\u00E1vky)\n- tritochalin\nOslaben\u00ED hypoglykemick\u00E9ho \u00FA\u010Dinku a tedy hyperglykemie se m\u016F\u017Ee objevit p\u0159i pod\u00E1v\u00E1n\u00ED n\u011Bkter\u00E9ho z n\u00E1sleduj\u00EDc\u00EDch p\u0159\u00EDpravk\u016F:\n- estrogeny a progestageny\n- saluretika, thiazidov\u00E1 diuretika\n- hormony \u0161t\u00EDtn\u00E9 \u017El\u00E1zy, glukokortikoidy\n- fenothiazinov\u00E9 deriv\u00E1ty, chlorpromazin\n- adrenalin a sympatomimetika\n- kyselina nikotinov\u00E1 (vysok\u00E9 d\u00E1vky) a jej\u00ED deriv\u00E1ty\n- laxativa (dlouhodob\u00E9 u\u017E\u00EDv\u00E1n\u00ED)\n- fenytoin, diazoxid\n- glukagon, barbitur\u00E1ty a rifampicin\n- acetazolamid\nAntagonist\u00E9 H2 receptor\u016F, beta-blok\u00E1tory, klonidin a reserpin mohou v\u00E9st bu\u010F k zes\u00EDlen\u00ED nebo k oslaben\u00ED hypoglykemick\u00E9ho \u00FA\u010Dinku."@cs . "1"^^ . . . . . . . . . . . . . . . . . . "9811"^^ . . . . . . . . . . . . . . . . . . . . . "11133"^^ . . . . . . . . . . . . . .